Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities
14. November 2024 09:00 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply & Manufacturing
Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease
08. November 2024 09:00 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline in NTM Abscessus Pulmonary Disease
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
14. Oktober 2024 07:31 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated Pathogens
31. Juli 2024 07:30 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline)
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia
18. Juli 2024 07:30 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA®
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024
18. April 2024 07:30 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and
Investigator-Initiated Pre-Clinical Studies at ESCMID Global (Formerly ECCMID)
Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement under BARDA Project BioShield Contract
05. März 2024 06:45 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Announces Positive Efficacy Data for NUZYRA®, Triggering Additional Procurement under BARDA Project BioShield Contract
Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher Bostrom to Chief Financial Officer
16. Januar 2024 09:00 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Pharma Promotes Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer, Christopher Bostrom to Chief Financial Officer
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
13. Dezember 2023 08:53 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings
07. September 2023 15:34 ET
|
Paratek Pharmaceuticals, Inc.
BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of...